Insmed(INSM)
Focus: Insmed is a public biotechnology company specializing in inhalable liposomal therapeutics across neurology, rare diseases, cardiovascular, respiratory, and ophthalmology indications. The company operates with 1-50 employees and maintains a public market presence (ticker: INSM).
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
92+12 this month
Growing — net +12 jobs in 30d
44 jobs added vs 32 removed. Steady team buildout.
Should You Work at Insmed?
AI assessmentBest fit for early-to-mid career professionals willing to accept financial volatility in exchange for exposure to rare disease innovation and inhalation therapeutics platform development.
Why Work Here
- Rare disease and respiratory focus positions you in high-unmet-need markets with ARIKAYCE (cystic fibrosis) generating peak revenue and BRINSUPRI (non-CF bronchiectasis) recently launched
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$305M
Key Products
Peak9.0yr
Core revenue driver at peak lifecycle with 9+ year patent runway; represents company's successful commercialization of liposomal inhalation technology.
Help build intelligence for Insmed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.